|
|
Vol. 22.42 – 13 December, 2021
|
|
|
|
|
|
|
|
In a Phase III clinical trial, scientists randomly assigned, in a 1:1 ratio, patients with large B cell lymphoma that was refractory to or had relapsed no more than 12 months after first-line chemoimmunotherapy to receive axicabtagene ciloleucel or standard care. [New England Journal of Medicine]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
In this open-label, Phase III study, investigators evaluated the efficacy and safety of beti-cel in adult and pediatric patients with transfusion-dependent β-thalassemia and a non–β0/β0 genotype.
[New England Journal of Medicine]
|
|
|
|
|
|
Public transcriptomic datasets confirmed B cell maturation antigen (BCMA) RNA expression in the caudate of normal human brains, suggesting that this may be an on-target effect of anti-BCMA therapy.
[Nature Medicine]
|
|
|
|
|
|
Researchers developed an anti-CD19 CAR comprised of the 4-1BB co-stimulatory and TNFRSF19 transmembrane domains, showing anti-tumor efficacy in an in vivo xenograft lymphoma model.
[Nature Communications]
|
|
|
|
|
|
The authors showed that SSEA-4 was more expressed in all pancreatic cancer cell lines examined but not detectable in normal pancreatic cells.
[Proceedings of the National Academy of Sciences of the United States of America]
|
|
|
|
|
|
Using unbiased transcriptome profiling of hypoxia-preconditioned mesenchymal stem cell and normoxic MSCs, scientists identified a lncRNA named lung cancer-associated transcript 1 (LUCAT1) under hypoxia.
[Molecular Therapy-Nucleic Acids]
|
|
|
|
|
|
The authors tested a new in vivo hematopoietic stem cell (HSC) transduction/selection approach in rhesus macaques using HSC-tropic, integrating, helper-dependent adenovirus vectors (HDAd5/35++) designed for expression of human γ−globin in red blood cells to treat hemoglobinopathies.
[Molecular Therapy-Methods & Clinical Development]
|
|
|
|
|
|
Scientists performed fully-mismatched heart transplantations and found combination treatment to result in prolonged allograft survival.
[Scientific Reports]
|
|
|
|
|
|
Researchers reported on a Phase II prospective monocentric trial examining the feasibility of stem cell mobilization with 12mg single dose pegfilgrastim in related donors. [Transfusion]
|
|
|
|
|
|
|
|
|
Beta cell replacement has emerged as an attractive therapeutic alternative to traditional exogenous insulin administration for management of type 1 diabetes.
[Trends in Pharmacological Sciences]
|
|
|
|
|
|
Scientists review and discuss the available published and ongoing clinical trials to explore the scientific background behind immunotherapy in the neoadjuvant context. [Human Vaccines & Immunotherapeutics]
|
|
|
|
|
|
|
|
Smart Immune SAS, a clinical stage T-cell medicine company utilizing its proprietary ex vivo biomimetic “thymus-in-a-dish” technology to develop T cell progenitors to reset a rapid, safe and full immune reconstitution, announced today a research collaboration with MSK.
[Smart Immune SAS]
|
|
|
|
|
|
Be The Match BioTherapies® and Vineti, the provider of the leading digital enterprise platform for cell and gene therapy supply chains, announced a collaboration to develop joint solutions that simplify and scale supply chain management of cell and gene therapies. [Vineti (GlobeNewsWire, Inc.)]
|
|
|
|
|
|
|
|
January 23 – 26, 2022 Santa Fe, New Mexico, United States
|
|
|
|
|
|
|
|
|
|
|
Memorial Sloan Kettering – New York City, New York, United States
|
|
|
|
|
|
|
iCamuno Biotherapeutics – Melbourne, Australia
|
|
|
|
|
|
|
Fred Hutch – Seattle, Washington, United States
|
|
|
|
|
|
|
Flanders Institute for Biotechnology – Leuven, Belgium
|
|
|
|
|
|
|
Genentech – San Francisco, California, United States
|
|
|
|
|
|